Annual Total Liabilities
$48.61 M
+$5.26 M+12.14%
31 March 2024
Summary:
Immunovant annual total liabilities is currently $48.61 million, with the most recent change of +$5.26 million (+12.14%) on 31 March 2024. During the last 3 years, it has risen by +$27.60 million (+131.37%). IMVT annual total liabilities is now at all-time high.IMVT Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$66.65 M
+$21.64 M+48.06%
30 September 2024
Summary:
Immunovant quarterly total liabilities is currently $66.65 million, with the most recent change of +$21.64 million (+48.06%) on 30 September 2024. Over the past year, it has increased by +$26.39 million (+65.56%). IMVT quarterly total liabilities is now at all-time high.IMVT Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMVT Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +12.1% | +65.6% |
| 3 y3 years | +131.4% | +119.7% |
| 5 y5 years | +10000.0% | +1427.8% |
IMVT Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +131.4% | at high | +200.7% |
| 5 y | 5 years | at high | >+9999.0% | at high | +1427.8% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Immunovant Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $66.65 M(+48.1%) |
| June 2024 | - | $45.02 M(-7.4%) |
| Mar 2024 | $48.61 M(+12.1%) | $48.61 M(+51.4%) |
| Dec 2023 | - | $32.10 M(-20.3%) |
| Sept 2023 | - | $40.26 M(-21.6%) |
| June 2023 | - | $51.36 M(+18.5%) |
| Mar 2023 | $43.34 M(-5.2%) | $43.34 M(+4.3%) |
| Dec 2022 | - | $41.56 M(+28.3%) |
| Sept 2022 | - | $32.40 M(+46.2%) |
| June 2022 | - | $22.16 M(-51.5%) |
| Mar 2022 | $45.74 M | $45.74 M(+20.3%) |
| Dec 2021 | - | $38.03 M(+25.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $30.34 M(+34.9%) |
| June 2021 | - | $22.50 M(+7.1%) |
| Mar 2021 | $21.01 M(+37.2%) | $21.01 M(+11.3%) |
| Dec 2020 | - | $18.88 M(+21.9%) |
| Sept 2020 | - | $15.49 M(-31.2%) |
| June 2020 | - | $22.52 M(+47.0%) |
| Mar 2020 | $15.32 M(+3926.8%) | $15.32 M(+3.8%) |
| Dec 2019 | - | $14.76 M(+238.3%) |
| Sept 2019 | - | $4.36 M(+6.0%) |
| June 2019 | - | $4.12 M(+1270.2%) |
| Mar 2019 | - | $300.40 K |
| Dec 2018 | $380.40 K | - |
FAQ
- What is Immunovant annual total liabilities?
- What is the all time high annual total liabilities for Immunovant?
- What is Immunovant annual total liabilities year-on-year change?
- What is Immunovant quarterly total liabilities?
- What is the all time high quarterly total liabilities for Immunovant?
- What is Immunovant quarterly total liabilities year-on-year change?
What is Immunovant annual total liabilities?
The current annual total liabilities of IMVT is $48.61 M
What is the all time high annual total liabilities for Immunovant?
Immunovant all-time high annual total liabilities is $48.61 M
What is Immunovant annual total liabilities year-on-year change?
Over the past year, IMVT annual total liabilities has changed by +$5.26 M (+12.14%)
What is Immunovant quarterly total liabilities?
The current quarterly total liabilities of IMVT is $66.65 M
What is the all time high quarterly total liabilities for Immunovant?
Immunovant all-time high quarterly total liabilities is $66.65 M
What is Immunovant quarterly total liabilities year-on-year change?
Over the past year, IMVT quarterly total liabilities has changed by +$26.39 M (+65.56%)